Research and Markets (http://www.researchandmarkets.com/research/de26ab/china_executive_su) has announced the addition of the "China Executive Summary of the Chinese Hospital Drug Utilization Volume 2nd Edition 2009" report to their offering.
The total Chinese pharmaceutical market had reached RMB 828.36 billion (US$ 120.84 billion, at an exchange rate of US $1 = RMB 6.83) with an annual growth rate (AGR) of 26.50% in 2008. The growth rate, as well as the absolute size of the rapidly-expanding Chinese pharmaceutical market, is no doubt astonishing. The categorization of the Chinese pharmaceutical market as one of the "emerging pharmaceutical market" may need to be reconsidered. Even though the current Chinese pharmaceutical market is still mainly a generic market, many of the innovative drugs have been rapidly up-taken by large Chinese hospitals in major cities. Some of the highly-priced oncology drugs, for example, erlotinib and trastuzumab, have made into the list of top 20 cancer drugs (by sales) in the last few years.
Many pharmaceutical companies have realized that just locking their eyes at the "mature" pharmaceutical markets (US, Europe and Japan) is no longer enough to sustain growth, especially for the future growth.
This Second Edition of the China Pharma Executive Summary provides hospital drug utilization data for 14 key therapeutic areas, including asthma, cancer, liver diseases, diabetes, hypertension, depression, allergy, dementia, benign prostate hyperplasia (BPH), ophthalmology, hyperlipoidemia, rheumatoid arthritis, dermatosis, and blood products, etc.
Key contents include: